ANI Pharma (ANIP) Tops Q1 EPS by 33c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
ANI Pharmaceuticals Reports First Quarter 2021 Results
May 7, 2021 6:50 AM EDT-- First quarter 2021 net revenues of $54.5 million; net income of $0.1 million and diluted earnings per share of $0.01 --
-- First quarter adjusted non-GAAP EBITDA of $18.9 million and adjusted non-GAAP diluted earnings per share of $1.04 --
-- Cortrophin® Gel sNDA re-filing on track for Q2 2021 submission --
-- Strengthened R&D engine and enhanced generics and CDMO business through pending acquisition of Novitium Pharma--
-- Expanded branded products portfolio through April 1 acquisition of Sandoz Inc. NDAs --
... More